MarketCap
Facebook
X
TelegramQuartalsbericht 2025-Q1
hinzugefügt 01.05.2025
Blueprint Medicines Corporation Operativer Cashflow 2011-2026 | BPMC
Operativer Cashflow Jährlich Blueprint Medicines Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -193 M | -437 M | -502 M | -299 M | 387 M | -278 M | -175 M | -120 M | -24.5 M | -31.7 M | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 387 M | -502 M | -167 M |
Operativer Cashflow Vierteljährlich Blueprint Medicines Corporation
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -54.5 M | - | - | - | -102 M | - | - | - | -123 M | - | -381 M | - | -133 M | - | -285 M | - | -126 M | - | 412 M | -210 M | -109 M | - | -233 M | -161 M | -80.2 M | - | -107 M | -52.4 M | -49.6 M | - | -85.1 M | -58.6 M | -31.1 M | - | -5.72 M | 12.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 412 M | -381 M | -93.5 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Graybug Vision
GRAY
|
-21.2 M | - | -11.23 % | $ 9.65 M |  USA |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 3.7 | -0.27 % | $ 1.11 B |  Canada |
 |
ADMA Biologics
ADMA
|
50.4 M | $ 16.5 | 0.73 % | $ 3.93 B | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
ANI Pharmaceuticals
ANIP
|
64 M | $ 76.81 | 0.93 % | $ 1.48 B | USA |
 |
Apellis Pharmaceuticals
APLS
|
45.3 M | $ 20.08 | -0.42 % | $ 2.53 B | USA |
 |
Aptorum Group Limited
APM
|
-1.19 M | $ 0.83 | 4.23 % | $ 4.53 M | China |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Athersys
ATHX
|
-76.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-57.3 M | - | - | $ 521 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.09 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | USA |
 |
Burford Capital Limited
BUR
|
181 M | $ 8.36 | -2.22 % | $ 1.39 B | Britain |
 |
Axsome Therapeutics
AXSM
|
-93.4 M | $ 164.46 | 0.25 % | $ 8.18 B | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
BridgeBio Pharma
BBIO
|
-446 M | $ 66.75 | 3.44 % | $ 12.8 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-72.5 M | - | - | $ 3.45 B | USA |
 |
Avid Bioservices
CDMO
|
11 M | - | - | $ 789 M | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-23.6 M | $ 2.84 | 1.07 % | $ 908 M |  Israel |
 |
Checkpoint Therapeutics
CKPT
|
-31.1 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-19.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
828 M | $ 60.85 | 3.96 % | $ 11.7 B | USA |
 |
Clovis Oncology
CLVS
|
-196 M | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
CTI BioPharma Corp.
CTIC
|
-81.2 M | - | - | $ 1.2 B | USA |
 |
CohBar
CWBR
|
-10.4 M | - | -15.44 % | $ 2.2 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-7.99 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-7.99 M | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-147 M | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Cabaletta Bio
CABA
|
-53.5 M | $ 3.41 | 4.77 % | $ 3.98 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
Capricor Therapeutics
CAPR
|
-25.6 M | $ 26.23 | 1.51 % | $ 702 M | USA |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Codexis
CDXS
|
-49.4 M | $ 1.1 | 12.24 % | $ 80.7 M | USA |
 |
Certara
CERT
|
96.3 M | $ 7.35 | 1.45 % | $ 1.18 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
-43 M | - | - | $ 105 M | USA |
 |
Evofem Biosciences
EVFM
|
-8.97 M | - | 7.55 % | $ 38.1 M | USA |